Thermo Fisher Scientific expanded COVID-19 test portfolio with two new antibody tests
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
-
-
OPKO Health’s BioReference Laboratories launched COVID-19 testing program for New York City schools
On Oct. 9, 2020, OPKO Health subsidiary BioReference Labs, New York City, the Department of Health, New York…
-
Pfizer Canada and BioNTech initiated rolling submission to Health Canada for SARS-CoV-2 vaccine candidate
On Oct. 9, 2020, Pfizer and BioNTech announced the initiation of a rolling submission to Health Canada for…
-
The CDC released a new national antibiotic resistance plan
On Oct. 9, 2020, the CDC released a new National Action Plan that directed federal agencies to accelerate…
-
Rigel announced first patients enrolled in trial of fostamatinib in hospitalized COVID-19 patients in collaboration with Inova
On Oct. 9, 2020, Rigel Pharma announced enrollment of the first patients in a multicenter, Phase 2 trial…
-
Biotechnology | COVID-19 | Disease | Medicine | NIH | Therapeutics
La Jolla Institute for Immunology awarded $1.4 million to study COVID-19 in Latino Americans
On Oct. 8, 2020, the La Jolla Institute for Immunology (LJI) announced it had been granted $1.4 million…
-
Emergent BioSolutionsﾒ COVID-19 product candidate included in NIH-sponsored phase 3 clinical trial
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
-
Johnson & Johnson announced EC approval of agreement to supply 200 million doses of COVID-19 vaccine candidate
On Oct. 8, 2020, Johnson & Johnson announced the European Commission, acting on behalf of the European Union…
-
Biotechnology | Infectious Disease | Influenza | Measles | Plague | Polio | Vaccine
DARPA awarded Moderna $56 Million to enable small-scale, rapid mobile manufacturing of vaccines and therapeutics
On Oct. 8, 2020, Moderna announced an agreement for a commitment of up to $56 million from the…
-
NIAID clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
-
Baricitinib had significant effect on recovery time, most Impactful in COVID-19 patients requiring oxygen
On Oct. 8, 2020, Eli Lilly and Incyte shared additional data showing baricitinib in combination with remdesivir reduced…
-
One stillbirth occurs every 16 seconds, according to first ever joint UN estimates
On Oct. 8, 2020, UNICEF, WHO, the World Bank Group and the Population Division of the United Nations…
-
NIH launched the Serological Sciences Network for COVID-19, announced grant and contract awardees
On Oct. 8, 2020, the National Cancer Institute (NCI) launched the Serological Sciences Network for COVID-19 (SeroNet), an…
-
Biotechnology | COVID-19 | Disease | Therapeutics | Vaccine
Relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review published
On Oct. 8, 2020, the relation between COVID-19 and Guillain-Barre syndrome in adults: a systematic review was published…
-
Gilead Sciences signed joint procurement agreement with European Commission for Vekluryﾮ (remdesivir)
On Oct. 8, 2020, Gilead Sciences and the European Commission signed a joint procurement agreement (JPA) that enabled…
-
Gilead Sciences updated supply and distribution of Vekluryﾮ (remdesivir) in the US
On Oct. 8, 2020, The New England Journal of Medicine (NEJM) published the final results from the National…
-
FDA awarded grants to fund clinical trials to advance development of products for treatment of rare diseases
On Oct. 8, 2020, the FDA announced that it had awarded six new clinical trial research grants to…
-
AMSP partnered with bioMerieux to facilitate supply of high-quality COVID-19 diagnostics
On Oct. 8, 2020, bioMerieux and the Africa Medical Supplies Platform (AMSP), announced a new partnership to facilitate…
-
Caladrius Biosciences opened study of CLBS119 to repair COVID-19-induced lung damage
On Oct. 8, 2020, Caladrius Biosciences announced that it had opened its proof-of-concept study of CLBS119 as a…
-
NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
-
SIGA announced Public Health Agency of Canada intent to purchase up to 33,300 courses of Oral TPOXX
On Oct. 8, 2020, SIGA Technologies announced that the Public Health Agency of Canada (PHAC) has issued an…
-
Yale Cancer Center received NIH grant to fund COVID-19 research in patients with hematologic cancers
On Oct. 8, 2020, the National Institutes of Health (NIH) awarded a Research Project Cooperative Agreement grant to…
-
Lilly announced supply of potential COVID-19 antibody therapy for low- and middle-income countries
On Oct. 8, 2020, Eli Lilly and the Bill & Melinda Gates Foundation, as part of the COVID-19…
-
RedHill Biopharma opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
-
RedHill Biopharma’s Opaganib COVID-19 study passed second independent committee review
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
-
Rentschler Biopharma contributed to manufacturing of COVID-19 mRNA vaccine
On Oct. 7, 2020, Rentschler Biopharma announced an agreement to serve as CDMO partner for BioNTech. As an…
-
Lilly updated progress of SARS-CoV-2 neutralizing antibody programs
On Oct. 7, 2020, Eli Lilly announced additional details on its SARS-CoV-2 neutralizing antibody programs ﾖ including interim…
-
Chemicals similar to those found in cannabis can inhibit bacterial virulence
On Oct. 7, 2020, UT Southwestern scientists showed that endocannabinoids, signaling molecules produced in the body that share…
-
Mateon announced first patient enrolled in ARTI-19 multicenter interventional study of Artshield against COVID-19
On Oct. 7, 2020, Mateon Therapeutics announced the first patient enrolled this week in its Phase IV study…
-
Kindred Biosciences announced expansion of Manufacturing agreement with Vaxart for COVID-19 and other vaccine candidates
On Oct. 7, 2020, Kindred Biosciences announced it had expanded an agreement with Vaxart for the manufacture of…
